Skip to main content
Gilead8-K: Bookings decline

Veklury sales drop 69% and Cell Therapy drops 18% in Q3 2026

Source: Autobound Signal API · 68 signals tracked for Gilead · updated

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.

What happened

Veklury sales decreased 69% to $86 million due to lower COVID-19 hospitalizations, while Cell Therapy sales dropped 18% to $355 million amid competitive headwinds.

Source

SEC EDGAROct 29, 2026

Current report (Form 8-K)

Gilead 8-K

Filing excerpt

Veklury sales decreased 69% to $86 million in the third quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.

sec.gov/Archives/edgar/data/882095/000088209526000037/gild-20261029.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
8-K: Bookings decline

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
10/29
Filed
Oct 29, 2026

The full record

From the Signal API record

Numbers

Dollar figure
$86M (Veklury sales in third quarter 2026)
Percent
-69% (decrease in Veklury sales compared to same period in 2025)

Details

CIK
882095
Accession number
0000882095-26-000037
Timeframe
Current quarter
Filing year
2026
Why it matters
Sales effectiveness tools
Signal category
Revenue

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Nov 3, 2026
signal_type
sec-8k
signal_subtype
bookingsDecline

Use this data

Get every 8-K signal for Gilead and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/d4da128f-4e68-4544-8730-d559942e821e returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.

{
  "signal_id": "d4da128f-4e68-4544-8730-d559942e821e",
  "signal_type": "sec-8k",
  "signal_subtype": "bookingsDecline",
  "detected_at": "2026-11-03T07:04:54.919+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "detail": "Veklury sales decreased 69% to $86 million due to lower COVID-19 hospitalizations, while Cell Therapy sales dropped 18% to $355 million amid competitive headwinds. Solution providers addressing cell therapy manufacturing efficiency or clinical commercialization could target teams working to counter these declines.",
    "metrics": {
      "pct": -0.69,
      "timeframe": "current_quarter",
      "pct_context": "decrease in Veklury sales compared to same period in 2025",
      "dollar_context": "Veklury sales in third quarter 2026",
      "dollar_millions": 86
    },
    "summary": "Veklury sales drop 69% and Cell Therapy drops 18% in Q3 2026",
    "excerpts": "Veklury sales decreased 69% to $86 million in the third quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000037/gild-20261029.htm",
    "filing_date": "2026-10-29",
    "filing_year": 2026,
    "fiscal_year_end": "10/29",
    "sales_relevance": "Sales effectiveness tools",
    "signal_category": "revenue"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.